| 注册
首页|期刊导航|中国药业|1例糖尿病合并甲状腺功能减退并发肝功能异常患者的药学监护

1例糖尿病合并甲状腺功能减退并发肝功能异常患者的药学监护

高羽 梁华 龙恩武 李根

中国药业2017,Vol.26Issue(1):82-85,4.
中国药业2017,Vol.26Issue(1):82-85,4.DOI:10.3969/j.issn.1006-4931.2017.01.0027

1例糖尿病合并甲状腺功能减退并发肝功能异常患者的药学监护

1 Case Study of the Treatment Methods for Liver Function Abnormal Patients with Hypothyroidism and Diabetes

高羽 1梁华 1龙恩武 2李根1

作者信息

  • 1. 四川省成都市妇女儿童中心医院,四川 成都 610000
  • 2. 四川省人民医院,四川 成都 610000
  • 折叠

摘要

Abstract

Objective To investigate the treatment method and drug selection for liver-function abnormalities with hypothyroidism and diabetes mellitus. Methods To analyze the possible causes of abnormal liver function from the aspects of disease factors and drug fac-tors. To analyze the drug selection of liver protection from the aspect of Hepatic function date and effects of pharmacologic ac-tions. Results The possible reasons that caused liver function abnormality of this patient who had hypothyroidism and diabetes mellitus was the chronically use of Prednisone Acetate Tablets and shortly united usage of Epalrestat Tablets, Mosapride Citrate Dispersible Tablets, Cefoxitin Injections, which resulted in impaired liver function. Magnesium Isoglycyrrhizinate Injection was selected to reach anti-inflammatory effect, Polyene Phosphatidylcholine to repair the cell membrane, and Ademetionine 1, 4-Butanedisulfonate Enteric Coated Tablets to be cholagogue. Conclusion The combination of Epalrestat Tablets, Mosapride Citrate Dispersible Tablets, Cefoxitin Injections will influence on liver function, which may cause liver-function abnormalities in patients who have basic disease of hypothyroidism and diabetes mellitus. At the base of controlling the basic disease and stopping using drugs that may have negative influence on diver func-tion, and using proper drugs to protect liver function can restore the liver function effectively.

关键词

肝功能异常/糖尿病/药物选择/药学监护

Key words

liver-function abnormalities/diabetes mellitus/drug selection/pharmacy care

分类

医药卫生

引用本文复制引用

高羽,梁华,龙恩武,李根..1例糖尿病合并甲状腺功能减退并发肝功能异常患者的药学监护[J].中国药业,2017,26(1):82-85,4.

中国药业

OACSTPCD

1006-4931

访问量0
|
下载量0
段落导航相关论文